SuperworthSanara MedTech profit margin SMTI
Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.
- Net margin, 12 months
- −29.2%
- Operating margin, 12 months
- 7.7%
- Net margin on a year earlier
- −18.9 pts
- Peer median
- 6.5%
Over the twelve months to Jun 30, 2026, Sanara MedTech kept −29.2% of its revenue as net profit, with an operating margin of 7.7% and a gross margin of 93.0%.
Five years earlier its net margin was −18.6%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −36.4% | 7.1% | 92.7% |
| FY2024 | −11.2% | −4.6% | 90.6% |
| FY2023 | −6.6% | −6.5% | 87.9% |
| FY2022 | −17.3% | −27.3% | 86.1% |
| FY2021 | −32.8% | −30.6% | 90.4% |
| FY2020 | −27.9% | −32.3% | 89.6% |
| FY2019 | −23.9% | −23.3% | 89.7% |
| FY2018 | −10.3% | −8.6% | 91.3% |
| FY2017 | 5.3% | 1.9% | 87.2% |
| FY2016 | −7.5% | −4.9% | 82.9% |
| FY2015 | −43.5% | −28.6% | 73.5% |
| FY2014 | −86.5% | n/a | 69.5% |
| FY2013 | n/a | n/a | 54.1% |
| FY2012 | n/a | n/a | 32.0% |
| FY2011 | n/a | n/a | 63.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −29.2% | −18.9 pts | 7.7% | |
| Q1 FY26 | −31.2% | −18.8 pts | 8.5% | |
| Q4 FY25 | −36.4% | −25.3 pts | 7.1% | |
| Q3 FY25 | −36.8% | −26.1 pts | 5.8% | |
| Q2 FY25 | −10.2% | −1.2 pts | 3.8% | |
| Q1 FY25 | −12.5% | −5.3 pts | −1.8% | |
| Q4 FY24 | −11.2% | −4.5 pts | −4.6% | |
| Q3 FY24 | −10.7% | +2.3 pts | −5.0% | |
| Q2 FY24 | −9.1% | +5.3 pts | −7.7% | |
| Q1 FY24 | −7.2% | +4.0 pts | −6.7% | |
| Q4 FY23 | −6.6% | +10.7 pts | −6.5% | |
| Q3 FY23 | −13.1% | +6.4 pts | −11.4% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Sanara MedTech's size, closest first, today.
| Company | Profit margin |
|---|---|
| SMTISanara MedTech | −29.2% |
| INFUInfuSystem | 6.0% |
| EMBCEmbecta | 8.6% |
| UTMDUtah Medical Products | 29.0% |
| PDEXPro DEX | 17.6% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| MOVMovado | 6.0% |
| KEQUKewaunee Scientific | 3.0% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| Peer median | 6.5% |
Where Sanara MedTech ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Sanara MedTech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.